The Sun Wise Study: Examining the impact of a personalised skin cancer prevention strategy among people with a history of skin cancer

Not Applicable

• Conditions: Skin cancer; Cancer - Non melanoma skin cancer; Cancer - Malignant melanoma

• Registration Number: ACTRN12623001035617
• Lead Sponsor: niversity of Sydney

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-09-22
• Last Update Posted: 4 March 2024

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 446

Inclusion Criteria

Patients aged 18+ years, who have previously been diagnosed with skin cancer (including melanoma, basal cell carcinoma, squamous cell carcinoma), are able to read and write English and competent to give informed consent, are contactable and available over the next 2 months for follow-up, are willing and able to wear UV watches for two seven-day periods and have as a private mobile phone to receive SMS sun protection reminders.

Exclusion Criteria

Under age 18 years, have never had a skin cancer, unable to read and write English, will not be contactable and available over the next 2 months for follow-up, unwilling or unable to wear up to two UV watches for two seven-day periods, or does not have a private mobile phone to receive SMS sun protection reminders.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome is total daily Standard Erythemal Doses (SEDs), an objective measure of ultraviolet radiation (UVR) exposure, measured at baseline and the 1 month follow-up timepoint. SEDs will be measured using time-stamped electronic dosimeter badges, mounted in light-weight custom-made wristbands attached to the left wrist (similar to wearing a watch) during daylight hours. UV dosimeters will be worn by all participants for 7 days at baseline and again 1 month after baseline. The data collected on weekdays will be averaged over 5 days and the data collected on weekends will be averaged over 2 days to enable an average weekly and average daily dose to be calculated.[ Over 7-day periods at baseline and again at follow-up at approximately 1 month after baseline]